EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In-silico study of approved drugs as potential inhibitors against 3CLpro and other viral proteins of CoVID-19

Imra Aqeel iD, Abdul Majid, Tahani Jaser Alahmadi, Areej Althubaity iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0325707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Imra Aqeel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Informatics Research Lab, Department of Computer & Information Sciences, Pakistan Institute of Engineering & Applied Sciences, Nilore, Isl…. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment, Coronavirus 3C Proteases. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah Bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global pandemic, due to the emergence of COVID-19, has created a public health crisis. It has a huge morbidity rate that was never comprehended in the recent decades. Despite numerous efforts, potent antiviral drugs are lacking. Repurposing of drugs presents a low-cost and rapid solution for finding new drugs by exploiting known drugs. In this study, we employed an integrated In-Silico approach using molecular docking and machine learning regression models to explore the potential inhibitors against key proteins of SARS-CoV-2. A library of 5903 drugs from the ZINC database was retrieved and screened against three crucial viral targets: Spike glycoprotein (7LM9) , main protease 3CLpro (7JSU) , and Nucleocapsid protein (7DE1). Binding affinities were predicted by using molecular docking, and subsequent predictive regression models, Decision Tree Regression (DTR), Gradient Boosting, XGBoost, Extra Trees, KNNR, and MLP, were constructed employing MACCS molecular fingerprints. Among them, the DTR model had better predictive performance, as indicated by the highest R² and lowest RMSE. The highest ranked compounds possessed good binding affinities (−12.6 to −19.7 kcal/mol) and favorable pharmacokinetics. Importantly, five novel candidate compounds, namely ZINC003873365, ZINC085432544, ZINC008214470, ZINC085536956, and ZINC261494640, had multi-target potential and optimal binding interaction. This computational analysis yields useful information for lead prioritization and sets the stage for additional in vitro and in vivo confirmation of these drug candidates to combat COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentCoronavirus 3C ProteasesMolecular Docking SimulationHumansCOVID-19Machine LearningSpike Glycoprotein, CoronavirusComputer SimulationDrug RepositioningCoronavirus Nucleocapsid ProteinsProtein Binding

Substanzen

Antiviral AgentsCoronavirus 3C ProteasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Coronavirus Nucleocapsid Proteins

Autor:innen und Institutionen

  • Biomedical Informatics Research Lab, Department of Computer & Information Sciences, Pakistan Institute of Engineering & Applied Sciences, Nilore, Islamabad, Pakistan.
  • Department of Information Systems, College of Computer and Information Sciences, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Cybersecurity Department, Umm Al Qura University, Makkah, Saudi Arabia.

ORCID-Profile: Imra Aqeel, Areej Althubaity

Förderung

  • Princess Nourah Bint Abdulrahman University

Zitieren

APA

Aqeel, I., Majid, A., Alahmadi, T. J., & Althubaity, A. (2025). In-silico study of approved drugs as potential inhibitors against 3CLpro and other viral proteins of CoVID-19. PLOS One. https://doi.org/10.1371/journal.pone.0325707

Vancouver

Aqeel I, Majid A, Alahmadi TJ, Althubaity A. In-silico study of approved drugs as potential inhibitors against 3CLpro and other viral proteins of CoVID-19. PLOS One. 2025. doi:10.1371/journal.pone.0325707

BibTeX
@article{Aqeel2025,
  author = {Aqeel, Imra and Majid, Abdul and Alahmadi, Tahani Jaser and Althubaity, Areej},
  title = {In-silico study of approved drugs as potential inhibitors against 3CLpro and other viral proteins of CoVID-19},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325707}
}
Kostenlos starten →